Health Trials

About this trial

Primary Objective of this study: To investigate the correlation between longitudinal quantitative dynamics of circulating tumor DNA (ctDNA) and HPV-derived cell-free DNA (HPV cfDNA) in peripheral blood and clinical prognosis among patients with recurrent and metastatic cervical cancer who achieved complete response following standard first-line systemic therapy.

Eligibility criteria

Qualifiers

Histopathologically confirmed cervical squamous cell carcinoma, adenocarcinoma, or adenosquamous carcinoma;

Patients with first recurrent or metastatic cervical cancer (including primary stage IVB disease);

Received standard first-line therapy (TP/TC regimen plus immunotherapy ± bevacizumab);

Achieved complete response (CR) following standard first-line treatment;

Disqualifiers

History of other malignant tumors within the past 2 years;

Pregnant or breastfeeding women;

Severe concomitant diseases, including: cardiovascular diseases (e.g., uncontrolled heart failure, unstable angina, etc.); pulmonary diseases (e.g., severe chronic obstructive pulmonary disease, interstitial pneumonia and other conditions impairing respiratory function); hepatic and renal dysfunction (e.g., decompensated liver cirrhosis, severe renal failure requiring dialysis, etc.);

Refusal to sign informed consent;

Trial design

Treatments tested in this trial

  • Biospecimen collection (peripheral blood and paraffin tumor tissue)

Treatment groups

60 Participants
are divided into 1 treatment group

Locations

This trial has no locations

Sponsors and collaborators

Zhejiang Cancer Hospital

Lead sponsor

Source ClinicalTrials.gov